Optimi Health (NASDAQ: OPTH) is moving MDMA into a Phase 3 clinical trial for post-traumatic stress disorder, with a particular focus on veterans and frontline workers.

‍

The Health Canada-authorized trial is expected to begin in 2027 and enroll up to 100 participants across multiple sites in Canada. Participants will include veterans as well as current and former military personnel, police officers, paramedics, firefighters, and healthcare workers.

‍

Participants will receive Optimi's synthetic MDMA during two supervised treatment sessions, spaced several weeks apart. The MDMA will be administered alongside psychotherapy, with patients monitored and evaluated after the final treatment. Researchers will measure changes using CAPS-5, a widely used clinician-administered test that measures the severity of PTSD symptoms.

‍

MDMA is better known as the active ingredient associated with the recreational drug ecstasy. But researchers have spent years studying pharmaceutical-grade MDMA as a potential treatment for PTSD.

‍

How it works

‍

The idea isn't simply to give someone MDMA and hope their symptoms disappear.

‍

MDMA can produce changes in fear, emotional openness, and feelings of trust that researchers believe may help some patients engage more effectively with trauma-focused psychotherapy. The drug is administered in a controlled setting with trained professionals rather than taken independently.

‍

Optimi's study will focus heavily on people who routinely face traumatic events through their work.

‍

A broader shift

‍

Optimi already has experience manufacturing MDMA for therapeutic use. The company operates a Health Canada-licensed pharmaceutical manufacturing facility in British Columbia and says clinics in Australia have been prescribing its MDMA since October 2024, where regulated access to MDMA-assisted therapy for PTSD is permitted.

‍

The Phase 3 study also represents a broader shift for Optimi.

‍

Just six days before announcing the MDMA trial, the company announced plans for a separate Phase 2 study involving as many as 200 patients testing naturally derived psilocybin-assisted therapy for major depressive disorder. Health Canada has also authorized that study.

‍

Neither program has proven that these treatments will ultimately win broader regulatory approval. Optimi specifically notes that the safety and efficacy of MDMA-assisted therapy for PTSD remain under investigation and that its MDMA products have not received market authorization from Health Canada. But Optimi is no longer just manufacturing psychedelic drugs for other researchers and treatment programs. It's now putting its own MDMA and psilocybin products into late- and mid-stage clinical trials that could determine whether they eventually become approved medicines.  And that’s not a trivial development.

‍